mBio (Oct 2021)
A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases
- Zhizhen Li,
- Jianping Wu,
- Ji Zhou,
- Baoshi Yuan,
- Jiqiao Chen,
- Wanchen Wu,
- Lian Mo,
- Zhipeng Qu,
- Fei Zhou,
- Yingying Dong,
- Kai Huang,
- Zhiwei Liu,
- Tao Wang,
- Deebie Symmes,
- Jingliang Gu,
- Eiketsu Sho,
- Jingping Zhang,
- Ruihuan Chen,
- Ying Xu
Affiliations
- Zhizhen Li
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Jianping Wu
- Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
- Ji Zhou
- Institute of Biology and Medical Sciences, Medical School of Soochow University, Suzhou, Jiangsu, China
- Baoshi Yuan
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Jiqiao Chen
- KCI Biotech (Suzhou) Inc., Suzhou, Jiangsu, China
- Wanchen Wu
- Joinn Laboratories (Suzhou), Co., Ltd., Suzhou, Jiangsu, China
- Lian Mo
- Aluda Pharmaceuticals, Inc., Menlo Park, California, USA
- Zhipeng Qu
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Fei Zhou
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Yingying Dong
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Kai Huang
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Zhiwei Liu
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Tao Wang
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- Deebie Symmes
- Aluda Pharmaceuticals, Inc., Menlo Park, California, USA
- Jingliang Gu
- Joinn Laboratories (Suzhou), Co., Ltd., Suzhou, Jiangsu, China
- Eiketsu Sho
- KCI Biotech (Suzhou) Inc., Suzhou, Jiangsu, China
- Jingping Zhang
- Institute of Biology and Medical Sciences, Medical School of Soochow University, Suzhou, Jiangsu, China
- Ruihuan Chen
- Luoda Biosciences, Inc., Chuzhou, Anhui, China
- Ying Xu
- Jiangsu Key Laboratory of Neuropsychiatric Diseases and Cambridge-Su Genomic Resource Center, Medical School of Soochow University, Suzhou, Jiangsu, China
- DOI
- https://doi.org/10.1128/mBio.02542-21
- Journal volume & issue
-
Vol. 12,
no. 5
Abstract
With the Delta variant currently fueling a resurgence of new infections in the fully vaccinated population, developing an effective therapeutic drug is especially critical and urgent in fighting COVID-19. In contrast to the many efforts to repurpose existing drugs or address only one aspect of COVID-19, we are developing a novel agent with first-in-class mechanisms of action that address both the viral infection and the overactive immune system in the pathogenesis of the disease.
